Press releases 2021

ADDvise Group has applied to trade on Nasdaq First North Premier and has today received an approval. ADDvise Group changes its listing on 23 December 2021. Nasdaq First North Premier gives companies the opportunity to prepare for listing on the Nasdaq Main Market by setting higher requirements for information disclosure, corporate governance and financial reporting.…

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholder of JTECH Medical Industries, Inc. (”JTECH”) regarding an acquisition of 100 percent of the shares in JTECH. JTECH is an American medtech company specialized in developing software and medical instruments to quantify patients’ range of motion, pain, and strength in muscles during…

ADDvise Group AB (publ) issued on 5 November 2021 a senior secured bond loan of SEK 250,000,000 within a total framework amount of SEK 500,000,000 on the Swedish bond market. The bonds carry a floating rate interest of STIBOR 3m + 7.25 per cent per annum (corresponding to a yield of approximately 6.6%) and matures…

ADDvise Group AB (publ) (the "Company" and together with its subsidiaries from time to time, the "Group") has instructed the agent for the Company's up to SEK 500,000,000 senior secured bonds with ISIN SE0015222088 (the "Bonds") to initiate a written procedure to request that bondholders vote in favour of (i) amending and restating items (i)…

ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from Oulu University Hospital in Finland regarding a long-term partnership for delivery of x-ray equipment and services during a ten-years period, with a total value of EUR 5 million. First installations are expected to take place during the year 2023. In accordance with…

ADDvise Group AB has today entered into a share purchase agreement with the owners of Sothern Life Systems, Inc. (“SLS”) regarding the acquisition of all shares of SLS in accordance with the letter of intent communicated via a press release dated August 30, 2021. Closing of the acquisition takes place today. SLS’ revenue for the…

ADDvise Group AB appoints Bengt Miller as interim Chief Financial Officer (CFO) and temporary member of the management team. He succeeds the current CFO, Aaron Wong, and will assume the role on 29 November 2021 until the 28[th] of February 2022 when the newly appointed CFO, Sebastian Robson, as previously communicated, commences his employment. Bengt…

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Masarat in Saudi Arabia, a company providing biosafety- and cleanroom services. The order is worth approximately USD 530,000 and involves design and construction of a cleanroom facility for the manufacturing of surgical sutures for Advanced Bio-Medical Industrial Co in Saudi Arabia. Delivery of…

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Masarat in Saudi Arabia, a company providing biosafety- and cleanroom services. The order is worth approximately USD 800,000 and involves design and construction of cleanroom facilities for controlled biosafety laboratories for IAU University in Saudi Arabia. Delivery of the order is planned to…

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Cordeel, a multinational construction company. The order is worth approximately USD 1.8 million and involves construction of cleanrooms for a pharmaceutical production facility in Bulgaria for TEVA Pharmaceutical. Delivery of the order is planned to take place during Q3 2022. – The market…

ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a subsequent senior secured bond issue (the “Subsequent Bond Issue) in an amount of 250 MSEK under the Company’s existing senior secured bond framework with ISIN SE0015222088. Following the Subsequent Bond Issue, the outstanding amount under the senior secured…

ADDvise Group AB (publ) has mandated Pareto Securities AB to arrange a series of fixed income investor meetings and, subject to inter alia market conditions, a subsequent bond issue under the company’s existing senior secured bond framework with ISIN SE0015222088 may follow. The net proceeds from the potential subsequent bond issue will be used to…

July – September 2021 Net revenue for the period was SEK 105.6 million (76.2), an increase of 38.6 %. Organic growth was 12.1 %. Adjusted EBITDA for the period was SEK 14.5 million (5.3) EBITDA for the period was SEK 13.3 million (9.4) Adjusted profit/loss for the period was SEK 3.0 million (-1.2) Basic earnings…

ADDvise Group AB (publ) appoints Sebastian Robson as new Chief Financial Officer (CFO) and member of the executive management team. He succeeds the current CFO, Aaron Wong, and will commence his employment no later than 28 February 2022. Sebastian’s most recent position is as CFO of Hexicon AB (publ), listed on Nasdaq First North. Sebastian…

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Poly Pharmaceuticals, Inc. (”Poly Pharma”) regarding an acquisition of 100 percent of the shares in Poly Pharma. Poly Pharma is an American pharmaceutical company specializing in the development, production and marketing of over-the-counter generic pharmaceuticals for treatment of coughs, colds, allergies,…

In accordance with the resolution at the 2021 annual general meeting of ADDvise Group AB, the nomination committee for the annual general meeting 2022 shall be composed of representatives of the three largest shareholders by votes listed in the shareholders’ register, which is maintained by Euroclear Sweden as of 30 June 2021, and the chairman…

Year-End Report 2021 (Jan-Dec)                                 2022-02-24 Last day for shareholders to request                            2022-03-18 an item to be included to the agenda of the Annual General Meeting Interim Report (Jan-March 2022)                       …

ADDvise Group AB (publ) (“ADDvise” and the “Company”) notes positive price movements in the Company's shares. ADDvise's share of series A carries one vote and share of series B carries one tenth of a vote, and besides this difference, the Company is not aware of any information concerning the Company which explains the difference between…

ADDvise Group AB raises its long-term EBITDA financial target from 15% to 20%. ADDvise also raises its long-term revenue growth target from 20% to 25%. Other long-term financial goals remain unchanged. For the financial year 2022, on a pro forma basis rolling 12 months, ADDvise expects to reach revenue of SEK 1 billion with an…

ADDvise Group AB has today entered into a share purchase agreement with the owner of Graham Medical Technologies, LLC (“GraMedica”) regarding the acquisition of all the outstanding shares of GraMedica in accordance with the letter of intent communicated via a press release dated 10[th] May 2021. Closing of the acquisition takes place today. GraMedica’s revenue…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER…

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Southern Life Systems, Inc. (”SLS”) regarding an acquisition of 100 percent of the shares in SLS. SLS is an American medtech company that is market leading in providing equipment and software for monitoring patients in long-term care. SLS has developed the…

ADDvise strengthens its Group management and recruits Fredrik Mella as COO. Fredrik has extensive international experience in the Medtech industry and has held key positions such as CEO, sales manager, COO and board member.

ADDvise Group AB (publ) has today completed the acquisition of all shares in Medisuite, LLC in accordance with the share purchase agreement as previously communicated via a press release on 30 July 2021. Medisuite will be consolidated into ADDvise’s financial reporting as of August 2021. The local management of Medisuite and its operational business structure…

ADDvise Group AB has today entered into a share purchase agreement with the owner of Medisuite LLC regarding the acquisition of all the outstanding shares of Medisuite, LLC in accordance with the letter of intent communicated via a press release dated 24[th] May 2021. Closing of the acquisition is expected to take place in August…

Aaron Wong, CFO and member of the management team of ADDvise Group AB (publ) since October 2018, has today announced that he will step down from his position as Chief Financial Officer to focus on his family and to pursue other opportunities. Aaron will remain as CFO until 28[th] January 2022, and the process of…

April – June 2021 Net revenue for the period was SEK 117.6 million (101.8) EBITDA for the period was SEK 15.8 million (15.1) EBITA for the period was SEK 13.3 million (13.1) Profit/loss for the period was SEK 0.1 million (8.3) Basic earnings per share for the period amounted to SEK 0.00 (0.07) Orders received…

ADDvise Group AB (publ) issued on 21 May 2021 a senior secured bond loan of SEK 250,000,000 within a total framework amount of SEK 500,000,000 on the Swedish bond market. The bonds carry a floating rate interest of STIBOR 3m + 7.25 per cent per annum and matures 21 May 2024. ADDvise has applied for…

ADDvise Group AB (publ) (”ADDvise”) has today completed the acquisition of all shares in MRC Systems FZE (”MRC”). The signing of the share purchase agreement has been communicated to the market via a press release on 16 February 2021. The total purchase price amounts to USD 8.00 million, of which USD 4.50 million has been…

We refer to the outstanding up to SEK 240,000,000 senior secured callable bonds issued by ADDvise Group AB (publ) (the "Company") with ISIN: SE0010298166 (the "Bonds") and to the terms and conditions of the Bonds (the "Terms and Conditions"). Reference is further made to a call notice dated 21 May 2021, in which the Company…

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Medisuite, LLC (”Medisuite”) regarding an acquisition of 100 percent of the shares in Medisuite. Medisuite is an American online pharmacy that specializes in medication for men’s health. The prescription medication that is marketed by Medisuite is mainly used for treatment of…

ADDvise Group AB (publ) (“ADDvise") hereby announces that ADDvise’s up to SEK 240,000,000 senior unsecured callable floating rate bonds with ISIN SE0010298166 (the "Bonds"), will be redeemed in advance in accordance with Clause 8.3 (Voluntary total redemption (call option)) of the terms and conditions of the Bonds. The redemption date will be 18 June 2021.…

ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a senior secured bond loan with an initial volume of 250 MSEK within a framework of 500 MSEK. The bond has a tenor of three years and carries interest at an annual rate of 3 months STIBOR plus 725…

ADDvise Group AB (publ) ("ADDvise" or the "Company") has mandated Pareto Securities AB to investigate the possibility of a senior secured bond issue with an expected volume of SEK 250,000,000 and a tenor of three years. The proceeds from the potential bond issue will be used to repay the Company's outstanding bonds and other credit…

ADDvise Group AB’s subsidiary Labrum AB has received an order from Takura AB, a company specialized in clinical phase cell therapy, worth approximately SEK 9 million. The order involves construction of a cleanroom including laboratory equipment to the production facility for cell therapy that Takura AB is going to build, through its subsidiary CellCo and…

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholder of Graham Medical Technologies, L.L.C. (“GraMedica”) regarding an acquisition of 100 percent of the shares in GraMedica. GraMedica is specialized in the development of orthopedic implants and stents for feet and ankle surgery. GraMedica was founded in 2003, and since, the company…

January – March 2021 Net revenue for the period was SEK 87.7 million (83.7) EBITDA for the period was SEK 8.9 million (5.4) EBITA for the period was SEK 6.9 million (3.4) Profit/loss for the period was SEK 2.5 million (-2.5) Basic earnings per share for the period amounted to SEK 0.02 (-0.02) Orders received…

Today, on 31 March 2021, ADDvise Group AB (publ) is publishing its annual report for 2020. The annual report is available on ADDvise’s website: www.addvisegroup.se. The annual report is published in Swedish and English. The Swedish version represents the original.   For further information, please contact: Rikard Akhtarzand, CEO +46 765-25 90 71 rikard.akhtarzand@addvisegroup.se Important information:…

To the annual general Meeting (AGM) of ADDvise Group AB (publ) on 23 April 2021, the nomination committee has decided to propose the re-election of the current board members Rikard Akhtarzand, Fredrik Celsing, Staffan Torstensson and Erland Pontusson as members of the board of directors. In addition, the nomination committee proposes the election of Johanne…